DelveInsight's "Von Willebrand Disease (VWD) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Von Willebrand Disease (VWD) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Von Willebrand Disease (VWD) market shares of the individual therapies, a detailed current Von Willebrand Disease (VWD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms.
Von Willebrand Disease (VWD) Market Key Facts
- The total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017.
- The highest diagnosed prevalence of Von Willebrand disease (VWD) is estimated in the United States, with 11,336 diagnosed cases in 2017.
- The lowest prevalent population of Von Willebrand disease (VWD) was recorded in Japan.
- In the 7MM, females are affected more as compared to males, in case of Von Willebrand disease (VWD)
- According to a review article published by Masato Nishino, “the number in Japan has increased gradually up to 735 cases (0.56 per 105 persons), possibly, in parallel with the extent of concern about Von Willebrand disease (VWD)”.
- According to the National Hemophilia Foundation for all Bleeding Disorders - Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals.
Von Willebrand Disease (VWD) Market Forecast
Von Willebrand disease (VWD) Market Size is anticipated to increase in the coming years owing to the increasing prevalent population of VWD patients in the 7MM. The promising expanded recombinant therapies will also fuel the market growth.
The Von Willebrand Disease (VWD) market analysis section of the report helps to understand the current and forecasted Von Willebrand Disease (VWD) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Von Willebrand Disease (VWD) Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Key Companies in the Von Willebrand disease (VWD) Market include Shire, CSL- Behring, Octapharma, LFB Biomedicaments, Ferring Pharmaceuticals, Grifols Biological Inc., and many others. Von Willebrand disease (VWD) Therapies covered in the report include Wilate, Vonvendi, Voncento, Desmopressin, Wilfactin/Wilfact, Humate-P/Haemate P, and many more.
Von Willebrand disease (VWD) Epidemiology Segmentation
- Total Diagnosed Prevalent Population of Von Willebrand Disease
- Type-Specific Diagnosed Prevalent Population of Von Willebrand Disease
- Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease
- Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease
Von Willebrand Disease (VWD) Epidemiology Forecast
The Von Willebrand Disease (VWD) epidemiology section covers insights about historical and current Von Willebrand Disease (VWD) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Von Willebrand Disease (VWD) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Von Willebrand Disease (VWD) Market Forecast